Location History:
- Sutton, MA (US) (2013)
- Cambridge, MA (US) (2014)
- Northbridge, MA (US) (2014 - 2017)
Company Filing History:
4 out of 787 
1 out of 2,928 
Years Active: 2013-2017
Title: Tracey Lodie: Innovator in Anti-CXCR3 Antibodies
Introduction
Tracey Lodie is an accomplished inventor based in Northbridge, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of anti-CXCR3 antibodies. With a total of 4 patents to his name, Lodie is recognized for his innovative approaches to diagnosing and treating CXCR3-associated disorders.
Latest Patents
Lodie's latest patents include groundbreaking work on nucleic acids encoding anti-CXCR3 antibodies. These patents provide methods for using the antibodies to diagnose and treat conditions such as diabetes mellitus type I (T1D), especially in cases of new-onset T1D. The disclosed CXCR3 neutralizing antibodies represent a significant advancement in therapeutic options for patients suffering from these disorders.
Career Highlights
Throughout his career, Tracey Lodie has worked with notable organizations, including Genzyme Corporation and the University of Florida Research Foundation, Incorporated. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to impactful research.
Collaborations
Lodie has had the opportunity to work alongside talented individuals such as Michele Youd and Scott Eisenbeis. These collaborations have further enriched his research and development efforts in the biotechnology sector.
Conclusion
Tracey Lodie is a prominent inventor whose work on anti-CXCR3 antibodies has the potential to transform the treatment of diabetes mellitus type I and other related disorders. His innovative contributions continue to pave the way for advancements in medical science.